Merck & Company (6MK) Stock Forecast & Price Target

69 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6MK Analyst Ratings

Moderate Buy

13 Buy

5 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6MK Stock 12 Month Forecast

Average Price Target

€118.95

▲(2.47% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is €118.95 with a high forecast of €134.63 and a low forecast of €86.86. The average price target represents a 2.47% change from the last price of €116.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"64":"€64","135":"€135","81.75":"€81.8","99.5":"€99.5","117.25":"€117.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":134.6313539,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€134.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":118.94565156705882,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€118.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.858938,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€86.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[64,81.75,99.5,117.25,135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.38,115.01471953076923,116.64943906153846,118.28415859230769,119.91887812307692,121.55359765384615,123.18831718461539,124.8230367153846,126.45775624615383,128.09247577692307,129.7271953076923,131.36191483846153,132.99663436923078,{"y":134.6313539,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.38,113.8081270436199,114.23625408723981,114.66438113085972,115.09250817447963,115.52063521809954,115.94876226171945,116.37688930533936,116.80501634895927,117.23314339257918,117.66127043619909,118.089397479819,118.51752452343891,{"y":118.94565156705882,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.38,111.3399183076923,109.2998366153846,107.25975492307691,105.21967323076923,103.17959153846154,101.13950984615384,99.09942815384615,97.05934646153845,95.01926476923077,92.97918307692308,90.93910138461538,88.89901969230769,{"y":86.858938,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.923,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.698,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.087,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.133,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.794,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.912,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.742,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.712,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.469,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.509,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.769,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.98,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.38,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€134.63

Average Price Target€118.95

Lowest Price Target€86.86

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Louise Chen

Scotiabank

€134.63

Buy

15.98%

Upside

Reiterated

08/04/26

Scotiabank Sticks to Its Buy Rating for Merck & Company (MRK)

Jason Gerberry

Bank of America Securities

€122.47

Buy

5.51%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Rocket Pharmaceuticals (NASDAQ: RCKT) and Danaher (NYSE: DHR)

Asad Haider

Goldman Sachs

€119

Buy

2.51%

Upside

Reiterated

08/03/26

Merck Buy Rating Reaffirmed as Analyst Highlights Emerging HIV Franchise and Maintains $137 Price Target

Emily Field

Barclays

€121.6→€130.29

Buy

12.24%

Upside

Reiterated

07/29/26

Merck & Company (MRK) Receives a Buy from Barclays

Mohit Bansal

Wells Fargo

€130.29

Buy

12.24%

Upside

Reiterated

07/24/26

Wells Fargo Sticks to Its Buy Rating for Merck & Company (MRK)

Courtney Breen

Bernstein

€86.86

Hold

-25.17%

Downside

Reiterated

07/22/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Illumina (NASDAQ: ILMN)

Vamil Divan

Guggenheim

€125.95

Buy

8.50%

Upside

Reiterated

07/17/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and UnitedHealth (NYSE: UNH)

Trung Huynh

RBC Capital

€123.34

Buy

6.25%

Upside

Reiterated

07/16/26

RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)

Geoff Meacham

Citi

€108.57

Hold

-6.47%

Downside

Reiterated

07/15/26

Citi Sticks to Its Hold Rating for Merck & Company (MRK)

Terence Flynn

Morgan Stanley

€97.28→€98.15

Hold

-15.45%

Downside

Reiterated

07/15/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Annexon Biosciences (NASDAQ: ANNX) and Guardant Health (NASDAQ: GH)

Evan Seigerman

BMO Capital

€117.26→€123.34

Buy

6.25%

Upside

Reiterated

07/13/26

Merck price target raised to $142 from $135 at BMO CapitalMerck price target raised to $142 from $135 at BMO Capital

Chris Schott

J.P. Morgan

€117.26→€121.6

Buy

4.76%

Upside

Assigned

07/13/26

Merck price target raised to $140 from $135 at JPMorganMerck price target raised to $140 from $135 at JPMorgan

Rajesh Kumar

HSBC

€117.26→€130.29

Buy

12.24%

Upside

Reiterated

07/06/26

Merck price target raised to $150 from $135 at HSBCMerck price target raised to $150 from $135 at HSBC

Luisa Hector

Berenberg Bank

€99.89→€108.57

Hold

-6.47%

Downside

Reiterated

06/22/26

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

Michael Yee

UBS

€125.95

Buy

8.50%

Upside

Reiterated

06/02/26

Merck & Company (MRK) Receives a Buy from UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Louise Chen

Scotiabank

€134.63

Buy

15.98%

Upside

Reiterated

08/04/26

Scotiabank Sticks to Its Buy Rating for Merck & Company (MRK)

Jason Gerberry

Bank of America Securities

€122.47

Buy

5.51%

Upside

Reiterated

08/03/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Rocket Pharmaceuticals (NASDAQ: RCKT) and Danaher (NYSE: DHR)

Asad Haider

Goldman Sachs

€119

Buy

2.51%

Upside

Reiterated

08/03/26

Merck Buy Rating Reaffirmed as Analyst Highlights Emerging HIV Franchise and Maintains $137 Price Target

Emily Field

Barclays

€121.6→€130.29

Buy

12.24%

Upside

Reiterated

07/29/26

Merck & Company (MRK) Receives a Buy from Barclays

Mohit Bansal

Wells Fargo

€130.29

Buy

12.24%

Upside

Reiterated

07/24/26

Wells Fargo Sticks to Its Buy Rating for Merck & Company (MRK)

Courtney Breen

Bernstein

€86.86

Hold

-25.17%

Downside

Reiterated

07/22/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and Illumina (NASDAQ: ILMN)

Vamil Divan

Guggenheim

€125.95

Buy

8.50%

Upside

Reiterated

07/17/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK) and UnitedHealth (NYSE: UNH)

Trung Huynh

RBC Capital

€123.34

Buy

6.25%

Upside

Reiterated

07/16/26

RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)

Geoff Meacham

Citi

€108.57

Hold

-6.47%

Downside

Reiterated

07/15/26

Citi Sticks to Its Hold Rating for Merck & Company (MRK)

Terence Flynn

Morgan Stanley

€97.28→€98.15

Hold

-15.45%

Downside

Reiterated

07/15/26

Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Annexon Biosciences (NASDAQ: ANNX) and Guardant Health (NASDAQ: GH)

Evan Seigerman

BMO Capital

€117.26→€123.34

Buy

6.25%

Upside

Reiterated

07/13/26

Merck price target raised to $142 from $135 at BMO CapitalMerck price target raised to $142 from $135 at BMO Capital

Chris Schott

J.P. Morgan

€117.26→€121.6

Buy

4.76%

Upside

Assigned

07/13/26

Merck price target raised to $140 from $135 at JPMorganMerck price target raised to $140 from $135 at JPMorgan

Rajesh Kumar

HSBC

€117.26→€130.29

Buy

12.24%

Upside

Reiterated

07/06/26

Merck price target raised to $150 from $135 at HSBCMerck price target raised to $150 from $135 at HSBC

Luisa Hector

Berenberg Bank

€99.89→€108.57

Hold

-6.47%

Downside

Reiterated

06/22/26

Berenberg Bank Keeps Their Hold Rating on Merck & Company (MRK)

Michael Yee

UBS

€125.95

Buy

8.50%

Upside

Reiterated

06/02/26

Merck & Company (MRK) Receives a Buy from UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

3 Months

Asad HaiderGoldman Sachs

Success Rate

11/12 ratings generated profit

Average Return

+8.28%

Copying Asad Haider's trades and holding each position for 3 Months would result in 91.67% of your transactions generating a profit, with an average return of +8.28% per trade.

1 Year

Asad HaiderGoldman Sachs

Success Rate

12/12 ratings generated profit

Average Return

+28.28%

Copying Asad Haider's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.28% per trade.

2 Years

Asad HaiderGoldman Sachs

Success Rate

12/12 ratings generated profit

Average Return

+30.73%

Copying Asad Haider's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +30.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6MK Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6MK has received 31 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 6MK average Analyst price target in the past 3 months is 118.95.

Each month's total comprises the sum of three months' worth of ratings.

6MK Financial Forecast

6MK Earnings Forecast

Next quarter’s earnings estimate for 6MK is €1.96 with a range of €1.75 to €2.16. The previous quarter’s EPS was -€0.11. 6MK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Sales Forecast

Next quarter’s sales forecast for 6MK is €15.05B with a range of €14.55B to €15.63B. The previous quarter’s sales results were €14.42B. 6MK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Stock Forecast FAQ

What is DE:6MK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 118.95.

What is DE:6MK’s upside potential, based on the analysts’ average price target?

Merck & Company has 2.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Merck & Company a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy, which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.

What is Merck & Company’s share price target?

The average share price target for Merck & Company is 118.95. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €134.63 ,and the lowest forecast is €86.86. The average share price target represents 2.47% Increase from the current price of €116.08.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Merck & Company?

To buy shares of DE:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Merck & Company (6MK) Stock Forecast & Price Target

6MK Analyst Ratings

6MK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

6MK Analyst Recommendation Trends

6MK Financial Forecast

6MK Earnings Forecast

6MK Sales Forecast

6MK Stock Forecast FAQ

Detailed List of Analyst Forecasts